About Emergent What We Do COVID-19 UPDATES Careers Investors Newsroom Main navigation Toggle Menu Search 2021 News Releases Keyword Search Year 2021 Date Title PDF 11/11/21 Emergent BioSolutions Announces Stock Repurchase Program 11/04/21 Emergent BioSolutions Reports Financial Results For Third Quarter 2021 10/18/21 Emergent BioSolutions to Release Third Quarter 2021 Financial Results and Conduct a Conference Call on November 4, 2021 10/15/21 Emergent BioSolutions Announces Initiation of Pivotal Phase 3 Study Evaluating the Safety and Immunogenicity of Its Single-Dose Chikungunya Vaccine Candidate, CHIKV VLP 09/14/21 Emergent BioSolutions Secures Multi-Year Development and Manufacturing Agreement with Providence Therapeutics for its mRNA COVID-19 Vaccine Candidate, PTX-COVID19-B 08/25/21 Emergent BioSolutions’ COVID-19 Human Immune Globulin Product Candidate to be Evaluated in NIH-Sponsored Phase 3 Clinical Trial (INSIGHT-012) of Hyperimmune Intravenous Immunoglobulin for Outpatient Treatment of COVID-19 08/23/21 Emergent BioSolutions to Participate in Investor Conferences 07/29/21 Emergent BioSolutions Reports Financial Results For Second Quarter 2021 07/29/21 Emergent BioSolutions to Resume Manufacturing Covid-19 Vaccine at Bayview Facility 07/26/21 Reverse the Silence Campaign Casts a National Spotlight on Overdose Risks Associated with Opioid Use 07/15/21 Emergent BioSolutions to Release Second Quarter 2021 Financial Results and Conduct a Conference Call on July 29, 2021 06/11/21 COVID-19 Vaccine Drug Substance Manufactured by Emergent BioSolutions Authorized as Part of Johnson & Johnson’s Emergency Use Authorization 05/26/21 Emergent BioSolutions Announces Positive Two-Year Persistence Data From Phase 2 Study Evaluating CHIKV VLP, the Company’s Chikungunya Virus Virus-Like Particle Vaccine Candidate 05/06/21 Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 20, 2021 at 9:00am EDT 05/05/21 Emergent BioSolutions to Participate in Investor Conferences 04/29/21 Emergent BioSolutions Reports Financial Results for First Quarter 2021 04/21/21 Statement on Issuance of Form FDA 483 at Emergent Bayview Facility 04/15/21 Emergent BioSolutions to Release First Quarter 2021 Financial Results and Conduct a Conference Call on April 29, 2021 04/04/21 Emergent BioSolutions On Track with Respect to COVID-19 Contractual Commitments; Receives Modified Task Order from the U.S. Department of Health & Human Services to Support the Opportunity for Further Expansion of Manufacturing Capacity for Johnson & Johnson’s COVID-19 Vaccine 04/02/21 Emergent BioSolutions Announces Topline Data from NIAID Phase 3 ITAC Trial (INSIGHT-013) Evaluating Immunoglobulins as a Treatment for Hospitalized Patients with COVID-19 04/01/21 Company Statement: Emergent BioSolutions Statement on Status of Current Manufacturing of COVID-19 Vaccine at Company’s Baltimore Bayview Facility 03/01/21 Emergent BioSolutions to Participate in Investor Conferences 02/18/21 Emergent BioSolutions Reports Financial Results for Fourth Quarter and Full Year 2020 02/04/21 Emergent BioSolutions to Release Fourth Quarter and Full Year 2020 Financial Results and Conduct a Conference Call on February 18, 2021 01/25/21 Humanigen and Emergent BioSolutions Announce Contract Development and Manufacturing Agreement for Phase 3 COVID-19 Therapeutic Candidate Lenzilumab™ 01/10/21 Emergent BioSolutions Announces 2021 Financial Guidance, Provides Preliminary 2020 Results 01/04/21 Emergent BioSolutions to Participate in Investor Conferences Investor Relations Investors Governance News Financials Events Stock Resources Investor Toolkit Print Page RSS Feeds Email Alerts Online Investor Kit Investor FAQs Information Request QUICK LINKS Corporate Fact Sheet Shareholders Careers Contact Us Personal Information Request Form Menu Column One Company Overview Our Vision History Awards Innovation Menu Column Two Contract Manufacturing Products Pipeline Platforms & Technologies Manufacturing Expertise Menu Column Three Press Releases Featured Stories Videos Leadership Governance © 2021 Emergent BioSolutions Inc. All rights reserved. PRIVACY PRINCIPLES